SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Novo Nordisk Seeks Approval for Etavopivat

Novo Nordisk said it submitted etavopivat for approval to treat sickle cell disease.

NVO

Related stories